- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Progressive familial intrahepatic cholestasis (PFIC) |
|---|
|
| Cholestatic pruritus |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Because of the propylene glycol content, the recommended maximum dose of Livmarli in patients with moderately impaired renal function (creatinine clearance CrCl ≥ 30 and < 60 ml/min) is 570 mcg/kg/dag. Livmarli should not be used in patients with severely impaired renal function.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The safety profile of maralixibat is consistent across all indications and age groups.
Very common (> 10%): abdominal pain and diarrhea (median duration < 1 week), diarrhea.
Common (1-10%): rise in ALAT and ASAT, in part with an increase in bilirubin.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Check:
- Before treatment: the values of fat-soluble vitamins (A, D and E) and of the INR. If these vitamins are deficient, additional therapy should be prescribed;
- liver function values before and during treatment. Increases in ALAT (without increases in bilirubin) have been observed; their clinical significance is not known;
- during episodes of diarrhea on adequate hydration.
Conditions, drugs or surgical procedures that affect gastrointestinal motility or enterohepatic circulation of bile acids may affect the efficacy of maralixibat.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Bile acids and derivatives | ||
|---|---|---|
| A05AA02 | ||
| Other drugs for bile therapy | ||
|---|---|---|
| A05AX05 | ||
| BILE ACIDS AND DERIVATIVES | ||
|---|---|---|
| A05AA02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Reference
- Mirum Pharmaceuticals International B.V., SmPC Livmarli (EU/1/22/1704/001) Rev 7; 12-7-2024, www.emea.europa.eu
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
